Plasma natriuretic peptides levels and echocardiographic findings in late subclinical anthracycline toxicity

Pediatric Hematology and Oncology

Volumn 25, Issue 8, 2008, Pages 723-733

  Kantar, Mehmet ^a   Levent, Erturk ^a   Cetingul, Nazan ^a   Ulger, Zulal ^a   Ozyurek, Ruhi ^a   Aksoylar, Serap ^a   Kansoy, Savas ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Anthracycline; Cardiac toxicity; Children; Echocardiography; Natriuretic peptides

Indexed keywords

ANTHRACYCLINE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; IFOSFAMIDE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; CANCER SURVIVOR; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; EWING SARCOMA; FEMALE; HEART INDEX; HEART VENTRICLE FUNCTION; HUMAN; MALE; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SYSTOLIC DYSFUNCTION;

ADOLESCENT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ATRIAL NATRIURETIC FACTOR; CARDIOTOXINS; CHILD; CROSS-SECTIONAL STUDIES; CYCLOPHOSPHAMIDE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 57449089793     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010802435393     Document Type: Article

References (42)

1. Steinherz LJ, Steinherz PG, Tan CTC. Cardiac failure and dysrhytmias 6-19 years after anthracycline therapy: A series of 15 patients. Med Pediatr Oncol. 1995;24:352-361.
2. Goorin AM, Chauvenet AR, Perez-Atayde AR. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr. 1990;116:144-147.
3. Yeung ST, Yoong C, Spink J. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet. 1991;337:816-816.
4. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institute Goustave Roussy. Br J Cancer. 2004;91:37-44.
5. Prestor VV, Rakovec P, Kozelj M, et al. Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood. Pediatr Hematol Oncol. 2000;17:527-540.
6. Rathe M, Carlsen NLT, Oxhoj H. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;48:663-667.
7. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-815.
8. Pautanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003;21:2349-2356.
9. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-2636.
10. Nousiainen T, Jantunen E, Vanninen E, et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol. 1999;62:135-141.
11. Tikanoja T, Riikonen P, Perkkio M, et al. Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up children with cancer. Med Pediatr Oncol. 1998;31:73-78.
12. Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37:4-9.
13. Solymar L, Marky I, Mellander L. Echocardiographic findings in children treated for malignancy with chemotherapy including adriamycin. Pediatr Hematol Oncol. 1988;5:209-216.
14. Lipshultz SE, Rifai N, Sallan SE. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96:2641-2648.
15. Wassmuth R, Lentzsch S, Erdbruegger U, et al. Subclinical cardiotoxic effets of anthracyclines as assessed by magnetic resonance imaging: A pilot study. Am Heart J. 2001;141:1007-1013.
16. Agarwala S, Kumar R, Bhatnagar V, et al. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography. J Pediatr Surg. 2000;35:1786-1789.
17. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14:362-372.
18. Bossi G, Lanzarini L, Laudisa ML, et al. Echocardiographic evaluation of patients cured of childhood cancer: A single center study of 117 subjects who received anthracyclines. Med Pediatr Oncol. 2001;36:593-600.
19. Lenk MK, Zeybek C, Okutan V, et al. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography. Turk J Pediatr. 1998;40:373-383.
20. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1347-1352.
21. Kakedekar AP, Sandor GG, Fryer C, et al. Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients. Med Pediatr Oncol. 1997;28:22-26.
22. Turner-Gomes SO, Lands LC, Haklton J, et al. Cardiorespiratory status after treatment for acute lymphoblastic leukemia. Med Pediatr Oncol. 1996;26:160-165.
23. Iarussi D, Galderisi M, Ratti G, et al. Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clin Cardiol. 2001;24:663-669.
24. Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardic toxicity in childhood cancer survivors. J Clin Oncol. 2008;25:3635-3643.
25. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest. 1991;87:1402-1412.
26. Fossmann WG, Richter R, Meyer M. The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol. 1998;110:335-357.
27. Germanakis I, Kalmanti M, Parthenakis F, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol. 2006;108:212-215.
28. Pinarli FG, Oguz A, Tunaoglu FS, et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer. 2005;44:370-377.
29. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology (Am Soc Hematol Educ Program). 2004;118-145.
30. Sahn Dj, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation M-mode echocardiography: results of a survey of echocardiograhic measurements. Circulation. 1978;58:1072-1078.
31. Mercier JC, Disesa TG, Jarmakani JM, et al. Two-dimensional echocardiographic assessment of left ventricular volumes and ejection fraction in children. Circulation. 1982;65:962-969.
32. Colan SD, Borow KM, Neuman A. Left ventricular end-systolic wall stress velocity of fiber shortening relation: a load independent index of myocardial contractility. J Am Coll Cardiol. 1984;4:715-724.
33. Rowland DG, Gutgesell HP. Use of mean arterial pressure for non-invasive determination of left ventricular end systolic wall stress in infants and children. Am J Cardiol. 1994;74:98-99.
34. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
35. Tei C. New noninvasive index for combined systolic and diastolic ventricular function. J Cardiol. 1995;26:135-136.
36. Eidem BW, Sapp BG, Suarez CR, et al. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol. 2001;87:1120-1122.
37. Langer T, Stöhr W, Bielack S, et al. Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer. 2004;42:373-379.
38. Postma A, Bink-Boelkens MT, Beaufort-Krol GC, et al. Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol. 1996;26:230-237.
39. Rammeloo LAJ, Postma A, Sobotka-Plojhar MA, et al. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Group. Med Pediatr Oncol. 2000;35:13-19.
40. Creutzig U, Diekamp S, Zimmermann M, Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer. 2007;48:651-662.
41. Nousiainen T, Jantunen E, Vanninen E, et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol. 1998;61:347-353.
42. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 2000;104:158-163.